Endometrial Cancer Recurrent Clinical Trial
Official title:
A Phase II Study of ONC201 in Recurrent or Metastatic Type II Endometrial Cancer
This is a a Simon's two-stage, non-randomized, open label, 2-arm Phase II trial of ONC201 in women with metastatic or recurrent Type II endometrial cancer who failed at least 1 prior chemotherapy regimen.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05001282 -
A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRĪ±)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04030429 -
Crizotinib in c-MET Mutation Metastatic/Recurrent/Persistent Endometrial Cancer
|
Phase 2 | |
Recruiting |
NCT03621904 -
PROMOTE Study: Prediction of Response Of HorMOnal Treatment in Advanced and Recurrent Endometrial Cancer
|
||
Recruiting |
NCT02922764 -
A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer
|
Phase 1 | |
Recruiting |
NCT05410717 -
CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT03015129 -
A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer
|
Phase 2 |